Investment Rating - The report maintains an "Accumulate" rating for the company [1][11]. Core Views - The company achieved a revenue of 491 million yuan in Q1 2024, representing a year-on-year growth of 11.48% and a quarter-on-quarter growth of 5.14% [6][7]. - The net profit attributable to the parent company for Q1 2024 was 139 million yuan, a year-on-year increase of 1.88% [6][7]. - The company is focusing on expanding its product layout and increasing the scale of its X-ray core components business through a planned capital increase of no more than 1.45 billion yuan [11]. Financial Performance Summary - **Revenue Forecasts**: - 2022A: 1,549 million yuan - 2023A: 1,864 million yuan - 2024E: 2,352 million yuan - 2025E: 2,851 million yuan - 2026E: 3,406 million yuan - Year-on-year growth rates are projected at 30%, 20%, 26%, 21%, and 19% respectively [5]. - **Net Profit Forecasts**: - 2022A: 641 million yuan - 2023A: 607 million yuan - 2024E: 813 million yuan - 2025E: 1,025 million yuan - 2026E: 1,239 million yuan - Year-on-year growth rates are projected at 32%, -5%, 34%, 26%, and 21% respectively [5]. - **Earnings Per Share (EPS)**: - 2024E: 6.29 yuan - 2025E: 7.97 yuan - 2026E: 10.05 yuan [5]. Industry and Product Development - The company is expanding its CT core component production, focusing on domestic production capabilities [8][10]. - The global CT detector market was valued at approximately 1.68 billion USD in 2021, with an expected annual growth rate of around 4.3% from 2022 to 2027 [8]. - The company has made significant advancements in its R&D, with 62 new intellectual property applications in 2023, including 32 invention patent applications [7][8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance is under short-term pressure, but its deepening layout in the X-ray industry chain is promising [1] - The company achieved a revenue of 4.91 billion yuan in Q1 2024, a year-on-year increase of 11.48%, and a net profit of 1.39 billion yuan, up 1.88% year-on-year [3] - In 2023, the company reported a revenue of 18.64 billion yuan, a year-on-year growth of 20.31%, but a net profit decrease of 5.27% due to fair value losses on financial assets [4] Summary by Sections Financial Performance - In Q1 2024, the company reported a revenue of 4.91 billion yuan, with a net profit of 1.39 billion yuan, and a non-recurring net profit of 1.56 billion yuan [3] - For the full year 2023, the company achieved a revenue of 18.64 billion yuan, with a net profit of 6.07 billion yuan, and a non-recurring net profit of 5.91 billion yuan [3][4] Product Development and Market Position - The company launched several new products in 2023, generating over 4.15 billion yuan in revenue from new sensor technology products, with core component revenue doubling to nearly 1 billion yuan [4] - The company is focused on R&D, with an investment of 263 million yuan in 2023, representing 14.09% of its revenue [4] Future Outlook - The company expects revenues of 23.38 billion yuan in 2024, 28.73 billion yuan in 2025, and 34.51 billion yuan in 2026, with net profits projected at 8.24 billion yuan, 10.17 billion yuan, and 12.33 billion yuan respectively [5][6] - The company aims to enhance its market position by expanding its overseas customer base and improving domestic demand for medical and industrial applications [5]

Investment Rating - The report maintains a "Buy" rating for the company [1][4] Core Views - The company achieved a revenue of RMB 491 million in Q1 2024, representing a year-on-year growth of 11.48%, while the net profit attributable to shareholders was RMB 139 million, up 1.88% year-on-year [4] - The company is focusing on high-end manufacturing capabilities and has mastered core technologies in X-ray flat panel detectors [4] - A directed share issuance plan has been announced to raise up to RMB 1.45 billion for the construction of X-ray vacuum devices and comprehensive solutions [4] Financial Summary - The company’s revenue is projected to grow from RMB 1,864 million in 2023 to RMB 2,303 million in 2024, reflecting a growth rate of 23.6% [5][7] - The net profit is expected to increase from RMB 607 million in 2023 to RMB 834 million in 2024, with a growth rate of 37.3% [5][7] - The projected EPS for 2024 is RMB 8.18, with corresponding P/E ratios of 25.3 for 2024, 20.4 for 2025, and 16.4 for 2026 [4][5][7]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 260.12 CNY per share, compared to the current price of 206.98 CNY [3][8]. Core Insights - In 2023, the company reported a revenue of 1.864 billion CNY, a year-on-year increase of 20.31%, while the net profit attributable to shareholders was 607 million CNY, a decrease of 5.27% due to fair value changes in held stocks [1][2]. - The gross margin for 2023 was 57.84%, showing a slight increase of 0.50 percentage points year-on-year, although it decreased to 53.33% in Q1 2024 [1]. - The company has seen rapid revenue growth from new products, particularly in high-voltage generators and new sensor technologies, with revenues exceeding 415 million CNY [1]. - The company plans to expand its production capacity for X-ray vacuum devices, aiming to raise up to 1.45 billion CNY for this initiative [1]. Financial Summary - The company’s revenue is projected to grow from 2.377 billion CNY in 2024 to 3.647 billion CNY in 2026, with respective growth rates of 27.5% and 23.3% [2][7]. - The net profit is expected to increase from 884 million CNY in 2024 to 1.422 billion CNY in 2026, with growth rates of 45.6% and 26.2% [2][7]. - The earnings per share (EPS) is forecasted to rise from 8.67 CNY in 2024 to 13.94 CNY in 2026 [2][7]. - The company’s price-to-earnings (P/E) ratio is projected to decrease from 23.87 in 2024 to 14.85 in 2026, indicating a more attractive valuation over time [2][7].

Financial Performance - The company's operating revenue for Q1 2024 was ¥490,911,525.92, representing an increase of 11.48% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2024 was ¥139,287,790.89, reflecting a growth of 1.88% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥155,573,268.23, which is an increase of 6.00% compared to the previous year[4] - Total operating revenue for Q1 2024 reached ¥490,911,525.92, an increase of 11.5% compared to ¥440,366,786.18 in Q1 2023[18] - The total profit for Q1 2024 is approximately ¥154.16 million, compared to ¥148.71 million in Q1 2023, representing an increase of about 3.0%[19] - The net profit for Q1 2024 is approximately ¥137.16 million, up from ¥134.98 million in Q1 2023, reflecting a growth of about 1.6%[19] - The basic earnings per share for Q1 2024 is ¥1.37, compared to ¥1.34 in Q1 2023, indicating an increase of approximately 2.2%[19] - The company reported a net profit margin improvement, with net profit for Q1 2024 showing resilience despite rising costs[18] Research and Development - The total R&D investment for Q1 2024 amounted to ¥68,541,759.76, accounting for 13.96% of operating revenue, an increase of 0.9 percentage points year-over-year[5] - R&D expenses increased to ¥68,541,759.76 in Q1 2024, compared to ¥57,527,080.59 in Q1 2023, reflecting a growth of 19.1%[18] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥8,081,355,865.21, up 7.59% from the end of the previous year[5] - Total assets as of Q1 2024 amounted to ¥8,081,355,865.21, an increase from ¥7,511,348,212.00 in the previous year[16] - Total liabilities for Q1 2024 were ¥3,583,352,371.48, compared to ¥3,158,323,975.51 in Q1 2023, marking an increase of 13.4%[16] - Long-term borrowings increased significantly to ¥1,547,895,492.31 in Q1 2024 from ¥382,100,000.00 in Q1 2023[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,321[9] - The total number of shares held by the top 10 shareholders accounted for 66.88% of the total shares, with the largest shareholder holding 16.35%[10] - The company reported that the top shareholder, Shanghai Yiyuan He Rui Investment Consulting Co., Ltd., holds 16,681,913 shares[10] - The company has not reported any significant changes in the participation of major shareholders in margin trading and securities lending activities[12] Cash Flow - The net cash flow from operating activities was negative at -¥42,258,174.73, indicating a significant cash outflow during the quarter[4] - Cash inflow from operating activities for Q1 2024 is approximately ¥408.23 million, compared to ¥354.19 million in Q1 2023, marking an increase of about 15.3%[21] - Cash outflow from operating activities for Q1 2024 is approximately ¥450.49 million, up from ¥395.26 million in Q1 2023, which is an increase of about 14.0%[21] - The net cash flow from operating activities for Q1 2024 is approximately -¥42.26 million, slightly worse than -¥41.08 million in Q1 2023[21] - Cash inflow from financing activities for Q1 2024 is approximately ¥1.18 billion, significantly higher than ¥2.08 million in Q1 2023[23] - The net cash flow from financing activities for Q1 2024 is approximately ¥879.85 million, compared to -¥263.49 million in Q1 2023, showing a substantial improvement[23] Other Information - The company received government subsidies amounting to ¥11,455,831.87, which positively impacted its financial performance[6] - The company's inventory decreased slightly to ¥767,290,730.26 from ¥781,841,288.64, indicating a decline of approximately 1.8%[14] - Accounts receivable increased to ¥726,972,325.00 from ¥604,587,580.89, representing a growth of about 20.2%[14] - The total amount of receivables from notes increased to ¥81,207,159.21 from ¥49,852,089.98, marking a growth of approximately 62.8%[14] - The company has not disclosed any new product developments or technological advancements during the reporting period[13] - There were no significant mergers or acquisitions reported in the first quarter of 2024[13] - The company has not provided any specific guidance for future performance in the upcoming quarters[13]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2024-031 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会 的公告 （一）会议召开时间：2024 年 5 月 29 日 14:00-15:00 重要内容提示： （http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 5 月 22 日(星期三) 至 5 月 28 日(星期二)16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 （ir@iraygroup.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海奕瑞光电子科技股份有限公司（以下简称"公司"）分别于 2024 年 4 月 20 日、2024 年 4 月 30 日在上海证券交易所网站（ ...

Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [1][3] Core Views - The company achieved a revenue of RMB 1.864 billion in 2023, representing a year-on-year growth of 20.31%. The net profit attributable to the parent company was RMB 607 million, a decrease of 5.27% year-on-year, while the net profit excluding non-recurring items was RMB 591 million, showing a growth of 14.43% year-on-year [3][4] - Both domestic and international businesses of the company maintained steady growth, with ongoing customer expansion efforts [3][4] Summary by Sections Financial Performance - In 2023, the company reported a revenue of RMB 1.864 billion, a 20.31% increase from the previous year. The gross profit margin improved to 57.84%, up by 0.5 percentage points year-on-year [4][5] - The fourth quarter of 2023 saw a revenue of RMB 467 million, a year-on-year increase of 4.87%, and a net profit of RMB 175 million, which is a 30.94% increase year-on-year [4][5] Business Segments - Domestic revenue reached RMB 1.121 billion, growing by 16.92%, while international revenue was RMB 680 million, up by 25.73%. The gross profit margin for domestic operations was 57.68%, down by 0.58 percentage points, while for international operations, it was 61.20%, an increase of 3.66 percentage points [4][5] Research and Development - The company invested RMB 263 million in R&D in 2023, accounting for 14.09% of its revenue. It is one of the few global manufacturers that master all major core technologies for digital X-ray detectors [4][5] Future Projections - The expected net profits for 2024, 2025, and 2026 are RMB 916 million, RMB 1.153 billion, and RMB 1.430 billion, respectively. Corresponding EPS for these years are projected to be RMB 8.98, RMB 11.31, and RMB 14.02 [4][5][6]

Investment Rating - The investment rating for the company is "Buy" [1][4][10] Core Views - The company achieved a revenue of 1.864 billion yuan in 2023, representing a year-on-year growth of 20.31%, while the net profit attributable to shareholders decreased by 5.27% to 607 million yuan [1][2] - The company plans to expand its production capacity for CMOS detectors, which is expected to enhance its market position in high-end medical applications [1][2] - The company is positioned as a leader in the domestic digital X-ray detector market, with significant growth potential driven by the trend of domestic substitution [1][2] Financial Performance Summary - Revenue for 2023 was 1.864 billion yuan, up 20.31% from the previous year, while the net profit attributable to shareholders was 607 million yuan, down 5.27% [1][2] - The gross margin for 2023 was 57.84%, with a net profit margin of 32.45% [1][6] - The company’s operating expenses showed a decrease in sales, management, and R&D expense ratios, while the financial expense ratio increased due to higher interest costs [1][6] Future Earnings Forecast - The forecasted net profit for 2024, 2025, and 2026 is expected to be 811 million yuan, 1.056 billion yuan, and 1.269 billion yuan respectively, with corresponding P/E ratios of 24, 18, and 15 [1][2][11] - The company anticipates a revenue growth of 27.5% in 2024 and 26.3% in 2025 [2][11] Market Position and Strategy - The company is expanding its product line and application areas, particularly in the high-end market for medical imaging [1][2] - The investment in the expansion of CMOS detector production capacity is aimed at meeting the demand for 150,000 units, indicating a strategic move to capture a larger market share [1][2]

2023年探测器业务承压，其他核心部件实现近亿元收入 奕瑞科技（688301.SH） 证券研究报告/公司点评 2024年4月20日 /机械设备 [Table_Industry] [评Ta级ble：_T增itle持] (维持) [公Ta司ble盈_F利in预anc测e]及 估值 市场价格：187.00元 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 1,549 1,864 2,352 2,851 3,406 分析师：王可 增长率yoy% 30% 20% 26% 21% 19% 执业证书编号：S0740519080001 净利润（百万元） 641 607 813 1,025 1,239 Email：wangke03@zts.com.cn 增长率yoy% 32% -5% 34% 26% 21% 每股收益（元） 6.29 5.96 7.97 10.05 12.15 每股现金流量 3.10 3.34 -0.53 8.19 10.12 分析师：郑雅梦 净资产收益率 16% 14% 16% 17% 17% 执业证书编号：S0740520080004 P/E 29.7 31.4 23. ...

上海奕瑞光电子科技股份有限公司 募集资金年度存放与使用情况 鉴证报告 2023 年度 ST 4 (2:37 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mc.6gev.cn）" 进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mc.6gev.cn） "进行空员 " " 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 关于上海奕瑞光电子科技股份有限公司 2023年度募集资金存放与使用情况专项报告的 鉴证报告 信会师报字[2024]第ZA11221号 上海奕瑞光电子科技股份有限公司全体股东: 我们接受委托,对后附的上海奕瑞光电子科技股份有限公司(以 下简称"贵公司"）2023年度募集资金存放与使用情况专项报告（以下 简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号――上市公司募集资金管理和使用的监管要求〈2022 年修订）》（证监会公告（2022）15号） ...